Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olutasidenib - Forma Therapeutics

Next Previous
Drug Profile

Olutasidenib - Forma Therapeutics

Alternative Names: FT 2102; IDH1-R132 Inhibitor FT-2102; REZLIDHIA

Latest Information Update: 05 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FORMA Therapeutics
  • Developer FORMA Therapeutics; Rigel Pharmaceuticals
  • Class Amines; Antineoplastics; Nitriles; Pyridines; Quinolines; Small molecules
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia
  • Phase II Glioma
  • Phase I/II Myelodysplastic syndromes; Solid tumours

Most Recent Events

  • 21 Feb 2025 Phase-II clinical trials in Glioma (In children, In adolescents, In adults, First-line therapy, Newly diagnosed, Late-stage disease, Combination therapy) in USA (PO) (NCT06161974)
  • 07 Dec 2024 Updated efficacy data from phase-I/II trial in Acute myeloid leukemia presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 30 Nov 2024 Olutasidenib licensed to Dr Reddys Laboratories in Latin America, South Africa, India, Australia, New Zealand, and certain countries in the Commonwealth of Independent States (CIS), Southeast Asia region and North Africa

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top